. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2015 Apr 8;13(10):1760–1766. doi: 10.1016/j.cgh.2015.03.029

Table 3.

Use of medications and history of operations in inflammatory bowel disease patients in relation to the status of anemia at the time of the evaluation

Medication	Group A^*	Group B^**	Group C^***	P value
Azathioprine or mercaptopurine (N, %)	57 (41.6 %)	47 (33.6)	34 (25.6)	.008^****
Methotrexate	6 (4.4)	13 (9.3)	13 (9.8)	.14
Biologics	32 (23.4)	45 (32.1)	37 (27.8)	.48
Oral iron	5 (3.6)	10 (7.1)	20 (15.0)	.002^*
IV iron	0 (0)	4 (2.9)	10 (7.5)	.003^*
History of IBD surgery	39 (28.5)	74 (52.9)	82 (61.6)	<.0001^*

Patients without anemia;

^**

with anemia for 1–2 years;

^***

with anemia for ≥3 years;

^****

group A vs group C

IV, intravenous; IBD, inflammatory bowel disease